Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Takeda Oncology Hopes Hit By CHMP Ninlaro Rejection; Appeal Planned

Executive Summary

An EMA advisory committee has set back Takeda Pharmaceutical Co. Ltd.’s oncology plans by rejecting Ninlaro as a treatment for multiple myeloma in the region, saying supporting data was inadequate for its backing but the Japanese company aims to appeal the decision.


Related Content

Takeda's Ninlaro Back In European Myeloma Race After CHMP Turnaround


Related Companies